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As we learn more about the associations between genes 
and disease, a growing number of diagnostic tests have 
been  developed  to  detect  mutations  that  increase  the 
risks of various diseases. However, anyone who wants to 
develop a diagnostic test or a treatment based on human 
genes faces a potential roadblock: gene patents. A 2005 
study [1] reported that 4,382 human genes (~20% of the 
total number in our genome) are covered by patents or 
other intellectual property claims. These patents cover a 
wide range of methods for assaying the DNA sequence of 
an  individual  for  the  presence  of  disease-associated 
mutations. For example, one of the most consequential 
gene  patents  covers  mutations  in  the  BRCA1  [2]  and 
BRCA2 [3] genes, which are associated with a significantly 
increased  risk  of  breast  and  ovarian  cancer  [4-6].  The 
BRCA gene patents, which are held by Myriad Genetics, 
cover all known cancer-causing mutations in addition to 
those that might be discovered in the future. No one can 
develop  a  commercial  diagnostic  test  or  a  treatment 
based  on  the  BRCA  gene  sequences  without  a  license 
from Myriad. Although a US federal court recently over-
turned seven of Myriad’s BRCA patents, Myriad is appeal-
ing the ruling, and it holds 16 other BRCA-related patents 
that it claims are unaffected by the court’s ruling [7].
As the cost of DNA sequencing falls, the idea of testing 
for  mutations  one  gene  at  a  time  is  rapidly  becoming 
obsolete. We are also rapidly approaching the day when it 
will be cheaper to fully sequence a genome before testing 
the sequence for all known genetic mutations associated 
with a given disease than to conduct multiple separate 
tests for each gene. Currently Myriad charges more than 
$3000 for its tests on the BRCA genes, while sequencing 
one’s entire genome now costs less than $20,000. Further-
more, once an individual’s genome has been sequenced, 
it  becomes  a  resource  that  can  be  re-tested  as  new 
disease-causing mutations are discovered.
In  contrast  to  whole-genome  sequencing,  standard 
methods for identifying mutations in BRCA1 and BRCA2 
use PCR to amplify the genome regions containing each 
mutation [8]. As more mutations are discovered, these 
tests need to be augmented with additional PCR assays, 
adding to their cost. The commercial assay available from 
Myriad Genetics interrogates a limited number of sites 
by  PCR  and  sequencing,  which  can  miss  clinically 
relevant  mutations;  for  example,  a  recent  study  [9] 
reported that 12% of women from high-risk families with 
deleterious  mutations  in  BRCA1  or  BRCA2  had  false 
negative  results  from  this  assay.  Even  if  the  test  were 
perfect,  a  gene-centered  approach  will  be  far  more 
expensive over time than a computational assay based on 
an individual’s genome, because the genome only needs 
to be sequenced once, after which it can be used to test 
all 22,000+ human genes.
Regardless of how easy it might be to test for mutations, 
the restrictive nature of the BRCA gene patents means 
that anyone wishing to examine any mutation in BRCA1 
or BRCA2 will have to obtain permission from the patent 
holder Myriad Genetics. This restriction applies even if 
testing your own genome. If you wanted to look at other 
genes, you would have to pay license fees for any of them 
that were protected by patents. In practice, although it 
may seem absurd, this means that before scanning your 
own genome sequence, you might be required by law to 
pay thousands of license fees to multiple patent holders.
We  believe  that  any  individual  should  be  allowed  to 
interrogate  his  or  her  genome  for  all  mutations  of 
interest, regardless of whether a private company claims 
to  ‘own’  the  rights  to  particular  gene  mutations.  To 
challenge the restrictive gene patenting system, we have 
developed  a  computational  assay  that,  as  a  proof-of-
concept, tests for 68 known variants of the BRCA1 and 
BRCA2  genes.  In  other  words,  we  empower  any 
individual using our software (whether this is a private 
individual, a clinician or a clinical or basic researcher) to 
test for these mutations and circumvent the gene patents. 
Here  we  demonstrate  the  method  on  the  publicly 
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Caucasian female, an African male and an Asian male 
[10].
We have made the software freely available (at http://
cbcb.umd.edu/software/BRCA-diagnostic) under an open 
source  license,  allowing  others  to  use,  modify  and 
redistribute it. The software is flexible and can easily be 
adapted  to  search  for  mutations  in  other  genes.  The 
method uses the raw sequence reads that are produced 
by  a  high-throughput  sequencer;  it  does  not  require 
genome assembly nor any other processing of the raw 
data.  This  software  provides  a  relatively  simple,  do-it-
yourself home testing method for interrogating a genome 
for the presence of mutations in the BRCA genes. All one 
needs, besides the software, is the sequence data from an 
individual human.
BRCA testing on three human genomes
We used the Bowtie short-read alignment program [11] 
to  screen  all  sequence  reads  against  the  BRCA1  and 
BRCA2  regions  (located  on  chromosomes  17  and  13, 
respectively)  and  against  a  set  of  68  known  mutations 
from the Online Mendelian Inheritance in Man (OMIM) 
database (see Methods). The size of the datasets ranged 
from 2.8 to 4.1 billion reads for each genome, with most 
reads  being  35-36  bp.  The  BRCA  genomic  regions  are 
each about 80-90 kb; with these small target sequences 
Bowtie  is  extremely  fast.  Using  only  a  single  2.4  GHz 
processor, Bowtie aligned reads at 127 million reads per 
hour, and alignment of the largest of our datasets took 
about  8  hours.  Thus  despite  the  enormous  number  of 
reads for each genome, screening was relatively fast.
In the Asian and African males, we found no evidence 
for any of the 68 deleterious mutations in BRCA1 and 
BRCA2. The Caucasian female had no mutations at 67 of 
the 68 sites, but she has a heterozygous mutation at one 
site  in  BRCA2.  At  this  location,  26  reads  match  the 
mutant base (C) and 24 reads match the normal base (A). 
This A-C mutation causes a single amino acid change, 
N372H,  in  exon  10,  which  in  homozygous  form  was 
originally reported to carry a 30-40% increased risk of 
breast  cancer  [12,13],  although  a  subsequent  study 
reported no increased cancer risk [14].
Note  that  the  68  mutations  used  in  this  proof-of-
concept assay do not represent a comprehensive list of 
BRCA mutations. We used OMIM as our primary source, 
but  other  databases  have  much  larger  lists  of  BRCA 
mutations  (for  example  the  Human  Gene  Mutation 
Database [15] lists 1,215 mutations for BRCA1 and 966 
for  BRCA2).  Most  of  these  additional  mutations  could 
easily be added to our test, simply by incorporating them 
in the sequence index file described below. The software 
can be extended to other genes by creating new index 
files for those genes.
If free software can be used to diagnose human genetic 
mutations, then individuals will be able to run their own 
tests in the privacy of their own homes. Fundamentally, 
this seems no different from measuring one’s temperature 
or blood pressure, but because of gene patents, the act of 
reading one’s own genome may require the permission of 
a private company. It is hard to envision how the patent 
holders  can  enforce  their  claims  in  this  scenario.  Our 
contention is that these patents never should have been 
awarded, and that no private entity should have rights to 
the naturally occurring gene sequences in every human 
individual.
Computational methods
A list of mutations in BRCA1 and BRCA2 were compiled 
from the OMIM database of human genetic diseases [16], 
identifiers  113705  and  600185.  We  created  indexes  for 
the Bowtie program [11] using the BRCA1 and BRCA2 
genomic regions including introns that span 81,155 bp 
and  84,193  bp,  respectively.  A  Bowtie  index  is  a 
specialized,  compressed  representation  of  a  genome 
sequence that enables very fast alignment. At the end of 
each  region,  we  concatenated  DNA  sequences  corres-
pond  ing  to  each  of  the  35  (BRCA1)  and  33  (BRCA2) 
mutations  listed  in  OMIM  (Figure  1).  These  extra 
sequences included 100 bp on either side of the mutant 
site. The mutations include insertions, deletions and base 
pair changes.
All three genomes were sequenced using the Illumina 
platform. The Asian genome (3,334,275,294 reads) was 
the first sequence of an Asian individual to be published 
[10].  The  African  (4,055,510,372  reads)  and  Caucasian 
(2,807,568,082  reads)  genome  data  were  generated  for 
the 1000 Genomes Project; the African male is a member 
of the Yoruba population in Ibadan, Nigeria (individual 
NA18507) and the Caucasian female is from a set of Utah 
residents  (CEPH)  with  European  ancestry  (individual 
NA12892). The Asian, African and Caucasian genomes 
were sequenced to 40x, 50x and 35x coverage, respec-
tively, which means that for each genomic position, an 
average  of  40,  50  and  35  sequence  reads  covered  that 
position.  The  DNA  samples  from  the  1000  Genomes 
Project are anonymous and have no associated medical 
or  phenotype  data,  and  all  sample  collection  followed 
ethical  guidelines  developed  for  that  project,  which 
permits the use of these data to study genetic diseases 
[17]. We then aligned all reads for each genome to both 
BRCA1 and BRCA2 using Bowtie version 0.12.3 [11] with 
default parameters, which reported only the best match 
for each read, allowing up to two mismatches. Because 
the indexes included both normal and mutant versions 
for each known sequence variant, the best match for a 
read  aligned  to  the  normal  version  unless  that  read 
derived from a mutant locus. Additional mutations can 
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sequence and rebuilding the Bowtie index.
We  created  new  programs  to  process  all  matching 
reads and report which if any reads matched each of the 
68 mutations in the diagnostic screen. For each mutation, 
the  program  reports  whether  the  individual  has  the 
mutation, and whether the individual is homozygous or 
heterozygous for that mutation. In creating this software, 
we are not violating the BRCA patents directly but any 
user would be, because even a noncommercial use (such 
as  examining  one’s  own  genome)  is  considered  to  be 
patent infringement [18].
Preparing for the genomic age
Finally, we recognize that there may be some controversy 
about giving ordinary individuals the ability to test their 
own  DNA,  without  also  providing  expert  genetic 
counseling.  As  pointed  out  in  a  recent  New  England 
Journal  of  Medicine  article:  “health  care  providers  are 
increasingly  bypassed  ...  as  patients  embrace  direct-to-
consumer  (DTC)  genetic  tests  and  turn  to  social 
networks  for  help  in  interpreting  their  results.  In  the 
future, a primary role of health care professionals may be 
to interpret patients’ DTC genetic test results and advise 
them about appropriate follow-up” [19]. The same article 
points out that “most primary care providers struggle to 
interpret single-gene tests (e.g., for BRCA1 and BRCA2) 
and are unprepared for the genomic age.” Nonetheless, 
the door to this new technology is already open and it 
cannot be closed. Rather than trying to keep patients in 
the dark, we need to embrace the technology and work 
harder to educate both physicians and patients about the 
power and the limitations of genetic tests.
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